Post job

Allogene Therapeutics overview

Industry
Biotechnology
Revenue
Employees
289
Founded in
Website
Organization type
Public
Social media
Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Based in South San Francisco, CA, Allogene Therapeutics is a medium-sized health care company with 289 employees and a revenue of $95,000.

Allogene Therapeutics's mission statement

To create and lead the next revolution in cancer treatment by delivering to patients the first AlloCAR T™ products for blood cancers and solid tumors.

In demand companies are hiring! Let Zippi apply for you!

Floating question marks illustration
-

Allogene Therapeutics employee reviews

Be the first to review!

Do you work at Allogene Therapeutics?

Help job seekers learn about working at Allogene Therapeutics

Job openings at Allogene Therapeutics
7 positions

On this page

Be the first to review Allogene Therapeutics

Anonymously rate your employee experience

Your opinion can help other job seekers

Do you like working at Allogene Therapeutics?

The team at Allogene Therapeutics

  • The founders of Allogene Therapeutics are David Chang, Arie Belldegrun and Joshua Kazam.
  • The key people at Allogene Therapeutics are David Chang, Arie Belldegrun and Joshua Kazam.
Key people
David Chang
Arie Belldegrun
Joshua Kazam

Allogene Therapeutics salaries

Average Allogene Therapeutics salary
$108,396
yearly
$52.11 hourly
Updated March 14, 2024

Rate Allogene Therapeutics' fairness in compensating employees.

Zippia waving zebra

Do you work at Allogene Therapeutics?

Is Allogene Therapeutics' workforce diverse and inclusive?

Allogene Therapeutics financial performance

4.5
Performance score

We calculated the performance score of companies by measuring multiple factors, including revenue, longevity, and stock market performance.

Allogene Therapeutics currently has 243.0K in revenue. Allogene Therapeutics's most recent quarter produced 43.0k (q3'2023).

Allogene Therapeutics annual revenue

$38M
$31M
$23M
$15M
$8M
$0
2021
2022
2023

Are you an executive, HR leader, or brand manager at Allogene Therapeutics?

Claiming and updating your company profile on Zippia is free and easy.

Allogene Therapeutics FAQs

Search for jobs

Most common locations at Allogene Therapeutics

Zippia gives an in-depth look into the details of Allogene Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Allogene Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Allogene Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Allogene Therapeutics. The data presented on this page does not represent the view of Allogene Therapeutics and its employees or that of Zippia.

Allogene Therapeutics may also be known as or be related to ALLOGENE THERAPEUTICS, INC., Allogene Therapeutics, Allogene Therapeutics Inc, Allogene Therapeutics Inc. and Allogene Therapeutics, Inc.